{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:04:58Z","timestamp":1784909098502,"version":"3.55.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>As our approaches to the management of adults with acute lymphoblastic leukemia (ALL) have become more effective, they have introduced new administrative complexities. These include challenges pertaining to medication administration and financial implications of treatment choices. Because approximately half of these patients are typically treated outside of larger referral centers, these difficulties are being passed on to clinicians in settings that rarely encounter this complex disease. Instead of an evidence-focused review on contemporary management of ALL in adults, this article seeks to highlight how some of these important medical advances may be difficult to operationalize outside of high-volume centers. It will also attempt to identify areas in which clinicians and investigators might consider modifying their respective approaches to mitigate how the realities of modern medical care may affect our ability to optimally manage these patients now and in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017584","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T19:58:38Z","timestamp":1759867118000},"page":"6345-6353","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Challenges and opportunities for improvement in the practical management of adults with acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-2425","authenticated-orcid":false,"given":"Ryan D.","family":"Cassaday","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"1","key":"2025122308411914400_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2025122308411914400_bib2","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"11","key":"2025122308411914400_bib3","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.bbmt.2019.08.014","article-title":"Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"DeFilipp","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2025122308411914400_bib4","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"issue":"3","key":"2025122308411914400_bib5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025122308411914400_bib6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2025122308411914400_bib7","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2025122308411914400_bib8","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2025122308411914400_bib9","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2025122308411914400_bib10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2025122308411914400_bib11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2025122308411914400_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10299","key":"2025122308411914400_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2025122308411914400_bib14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2025122308411914400_bib15","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2025122308411914400_bib16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"2025122308411914400_bib17","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"14","key":"2025122308411914400_bib18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2025122308411914400_bib19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"issue":"17","key":"2025122308411914400_bib20","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2025122308411914400_bib21","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025122308411914400_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025122308411914400_bib23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"36","key":"2025122308411914400_bib24","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.24.00490","article-title":"Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025122308411914400_bib25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025122308411914400_bib26","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"issue":"36","key":"2025122308411914400_bib27","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025122308411914400_bib28","volume-title":"Acute Lymphoblastic Leukemia (Version 2.2025)","year":"27  2025"},{"issue":"12","key":"2025122308411914400_bib29","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"2025122308411914400_bib30","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood.2022017035","article-title":"How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia","volume":"141","author":"Kopmar","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025122308411914400_bib31","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/cncr.34073","article-title":"Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia","volume":"128","author":"Garcia","year":"2022","journal-title":"Cancer"},{"issue":"6","key":"2025122308411914400_bib32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.32606","article-title":"Optimizing the use of the hyperCVAD regimen: clinical vignettes and practical management","volume":"126","author":"Rausch","year":"2020","journal-title":"Cancer"},{"issue":"12","key":"2025122308411914400_bib33","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Haematol"},{"issue":"19","key":"2025122308411914400_bib34","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025122308411914400_bib35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/10428194.2021.1975187","article-title":"Acute lymphoblastic leukemia (ALL) in adults: disparities in treatment intervention based on access to treatment facility","volume":"63","author":"Khullar","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2025122308411914400_bib36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/bloodadvances.2017014944","article-title":"Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study","volume":"2","author":"Muffly","year":"2018","journal-title":"Blood Adv"},{"issue":"12","key":"2025122308411914400_bib37","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/OP.23.00373","article-title":"Impact of specialized treatment setting on survival in adolescent and young adult ALL","volume":"19","author":"Muffly","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"21","key":"2025122308411914400_bib38","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"2025122308411914400_bib39","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"2025122308411914400_bib40","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025122308411914400_bib41","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41571-024-00948-1","article-title":"The high costs of anticancer therapies in the USA: challenges, opportunities and progress","volume":"21","author":"Jazowski","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"2025122308411914400_bib42","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJMc2402132","article-title":"Hospital prices for physician-administered drugs. Reply","volume":"390","author":"Robinson","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"2025122308411914400_bib43","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamainternmed.2022.1022","article-title":"Hospital-administered cancer therapy prices for patients with private health insurance","volume":"182","author":"Xiao","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2025122308411914400_bib44","unstructured":"Acute Inpatient Prospective Payment Systems. Updated 14 April 2025. Accessed 6 August 2025. https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/acute-inpatient-pps."},{"issue":"7 pt 2","key":"2025122308411914400_bib45","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1537-2995.2009.02260.x","article-title":"Hospital billing for blood processing and transfusion for inpatient stays","volume":"49","author":"McCue","year":"2009","journal-title":"Transfusion"},{"issue":"2","key":"2025122308411914400_bib46","first-page":"65","article-title":"Standardized review and approval process for high-cost medication use promotes value-based care in a large academic medical system","volume":"11","author":"Durvasula","year":"2018","journal-title":"Am Health Drug Benefits"},{"issue":"7","key":"2025122308411914400_bib47","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","article-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Jabbour","year":"2025","journal-title":"Lancet Haematol"},{"issue":"16 suppl","key":"2025122308411914400_bib48","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025122308411914400_bib49","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025122308411914400_bib50","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaoncol.2024.0967","article-title":"Dose-adjusted EPOCH plus inotuzumab ozogamicin in adults with relapsed or refractory B-cell ALL: a phase 1 dose-escalation trial","volume":"10","author":"Kopmar","year":"2024","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"2025122308411914400_bib51","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/blood-2024-208875","article-title":"Extended follow-up of dose-adjusted EPOCH (DA-EPOCH) plus inotuzumab ozogamicin (InO) in adults with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL): a safe and effective salvage therapy","volume":"144","author":"Kopmar","year":"2024","journal-title":"Blood"},{"key":"2025122308411914400_bib52","unstructured":"Testing the combination of inotuzumab ozogamicin and lower dose chemotherapy compared to usual chemotherapy for adults with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma. ClinicalTrials.gov identifier: NCT05303792. Updated 2 April 2025. Accessed 25 June 2025. https:\/\/clinicaltrials.gov\/study\/NCT05303792."},{"key":"2025122308411914400_bib53","unstructured":"Sequential treatment with ponatinib and blinatumomab vs chemotherapy and imatinib in newly diagnosed adult Ph+ ALL. ClinicalTrials.gov identifier: NCT04722848. Updated 23 January 2025. Accessed 25 June 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT04722848."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6345\/2474728\/blooda_adv-2025-017584-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6345\/2474728\/blooda_adv-2025-017584-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:41:29Z","timestamp":1766497289000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6345\/547632\/Challenges-and-opportunities-for-improvement-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":53,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017584","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,11]]}}}